Disability Annual Renewable Term (ART) Rider

A Disability Annual Renewable Term (ART) Rider is an optional add-on to a life insurance policy that provides disability income benefits in the event the policyholder becomes disabled. Here are the key features of this rider:

• Disability benefit amount: The rider will specify the amount of disability income benefits the policyholder will receive in the event of disability. The benefit amount is typically a percentage of the policy's face value, such as 1% to 2% per month.

• Waiting period: The rider will specify a waiting period, which is the length of time the policyholder must be disabled before benefits are paid. The waiting period may range from 30 to 180 days.

• Benefit period: The rider will also specify a benefit period, which is the length of time benefits will be paid. The benefit period may range from one to five years, or until the policyholder reaches a certain age.

• Definition of disability: The definition of disability in the rider is important to understand as it determines when the policyholder will be eligible to receive benefits. Some policies may define disability as being unable to perform the duties of the policyholder's own occupation, while others may define disability as being unable to perform any occupation.

• Renewability: The Disability ART Rider is typically renewable on an annual basis, meaning that the policyholder can choose to renew the rider each year as long as they continue to pay the premiums.

Next Up

According to Mployer Insights’ 2026 analysis of 76,000+ employer benefit plans, disability insurance remains a major market differentiator, with only 41% of U.S. employers offering short-term disability (STD) and 38% offering long-term disability (LTD). While 60% salary replacement serves as the national standard across both benefit types, standard plan designs disproportionately expose higher earners due to median benefit caps of $1,602/week for STD and $8,273/month for LTD. Furthermore, alignment between STD benefit durations (median 26 weeks) and LTD elimination periods (68% at 90 days) remains a critical area for plan structure optimization.
Welcome to our latest release. We are excited for you to try the new features.
According to Mployer Insights’ 2026 analysis of 50,000+ employer health plans, prescription drugs account for over 25% of total benefit expenses, with Tier 4 specialty drugs driving the majority of high-cost claims. While Tier 4 copays average $123 with coinsurance requirements in 31% of plans, individual oncology therapies like Darzalex Faspro ($170,800/yr) and Keytruda ($158,200/yr) frequently exceed average individual stop-loss deductibles ($141,938). To mitigate exposure, self-funded employers are increasingly turning to independent, transparent PBM models and biosimilar substitution—which yields up to a 73% net cost reduction per patient.